MEDI4736 monotherapy: Clinical Trials

2 trials of MEDI4736 monotherapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2

Follow MEDI4736 monotherapy: new trials by email Literature Review of MEDI4736 monotherapy trials Research Report on MEDI4736 monotherapy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
MEDI4736 monotherapy, tremelimumab+MEDI4736 - Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2CompletedAstraZeneca652015-11-162018-08-02
Study of Tremelimumab in Patients With Advanced Solid Tumors
Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy - Urothelial Bladder Cancer, Triple-negative Breast Cancer
Phase 2CompletedAstraZeneca642015-11-022023-11-15

Conditions studied

Anophthalmia with pulmonary hypoplasia (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

AstraZeneca (2)

Countries

Netherlands (2)  ·  South Korea (2)  ·  United States (2)  ·  Belgium (1)  ·  Canada (1)  ·  Germany (1)  ·  Poland (1)  ·  Spain (1)

Top investigators

Eileen M O'Reilly, M.D (1)  ·  Sharma Padmanee, MD, PhD (1)

Results publications

PMID 31318392

NIH funding

2015 (1)